Israel - English - Ministry of Health

inovamed ltd - rizatriptan as benzoate - tablets - rizatriptan as benzoate 10 mg - rizatriptan - for the acute treatment of migraine attacks with or without aura in adults.

Israel - English - Ministry of Health

inovamed ltd - rizatriptan as benzoate - tablets orodispersible - rizatriptan as benzoate 10 mg - rizatriptan - for the acute treatment of migraine attacks with or without aura in adults.

United States - English - NLM (National Library of Medicine)

direct rx - rizatriptan benzoate (unii: wr978s7qhh) (rizatriptan - unii:51086hbw8g) - rizatriptan benzoate tablets are indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old. information related to usage of rizatriptan benzoate in pediatric patients (6 to 17 years old) is approved for merck & co., inc.’s rizatriptan benzoate tablets. however, due to merck & co., inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric patient (6 to 17 years old) usage information. limitations of use rizatriptan benzoate tablets should only be used where a clear diagnosis of migraine has been established. if a patient has no response for the first migraine attack treated with rizatriptan benzoate, the diagnosis of migraine should be reconsidered before rizatriptan benzoate tablet is administered to treat any subsequent attacks. rizatriptan benzoate tablets are not indicated for use in the management of hemiplegic or basilar migraine [see contraindications (4)]. rizatriptan benzoate tablets are not indic

Ireland - English - HPRA (Health Products Regulatory Authority)

merck sharp & dohme ireland (human health) limited - rizatriptan - tablet - 5 milligram(s) - selective serotonin (5ht1) agonists; rizatriptan

Ireland - English - HPRA (Health Products Regulatory Authority)

merck sharp & dohme ireland (human health) limited - rizatriptan - oral lyophilisate - 5 milligram(s) - selective serotonin (5ht1) agonists; rizatriptan

Ireland - English - HPRA (Health Products Regulatory Authority)

merck sharp & dohme ireland (human health) limited - rizatriptan benzoate - tablet - 10 milligram(s) - selective serotonin (5ht1) agonists; rizatriptan

Ireland - English - HPRA (Health Products Regulatory Authority)

merck sharp & dohme ireland (human health) limited - rizatriptan benzoate - oral lyophilisate - 10 milligram(s) - selective serotonin (5ht1) agonists; rizatriptan

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rizatriptan benzoate, quantity: 7.265 mg (equivalent: rizatriptan, qty 5 mg) - tablet, orally disintegrating - excipient ingredients: sucralose; magnesium stearate; mannitol; crospovidone; microcrystalline cellulose; flavour - rizatriptan is indicated for the acute treatment of migraine attacks with or without aura.

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - rizatriptan benzoate (unii: wr978s7qhh) (rizatriptan - unii:51086hbw8g) - rizatriptan benzoate tablets are indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old. limitations of use - rizatriptan benzoate tablets should only be used where a clear diagnosis of migraine has been established. if a patient has no response for the first migraine attack treated with rizatriptan benzoate tablets, the diagnosis of migraine should be reconsidered before rizatriptan benzoate tablets are administered to treat any subsequent attacks. - rizatriptan benzoate tablets are not indicated for use in the management of hemiplegic or basilar migraine [see contraindications (4)] . - rizatriptan benzoate tablets are not indicated for the prevention of migraine attacks. - safety and effectiveness of rizatriptan benzoate tablets have not been established for cluster headache. rizatriptan benzoate tablets are contraindicated in patients with: - ischemic coronary artery disease (angina pectoris, history of myocardial infarction, or documented s

United States - English - NLM (National Library of Medicine)

proficient rx lp - rizatriptan benzoate (unii: wr978s7qhh) (rizatriptan - unii:51086hbw8g) - rizatriptan benzoate orally disintegrating tablets, usp are indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old. limitations of use rizatriptan benzoate orally disintegrating tablets, usp are contraindicated in patients with: risk summary   available human data on the use of rizatriptan in pregnant women are not sufficient to draw conclusions about drug-associated risk for major birth defects and miscarriage. in animal studies, developmental toxicity was observed following oral administration of rizatriptan during pregnancy (decreased fetal body weight in rats) or throughout pregnancy and lactation (increased mortality, decreased body weight, and neurobehavioral impairment in rat offspring) at maternal plasma exposures greater than that expected at therapeutic doses in humans [see animal data ]. in the u.s. general population, the estimated background risk of major birth defects and of miscarriage in clinically recognized pregnancies is 2% t